MaederML, GersbachCA. Genome-editing technologies for gene and cell therapy. Mol Therapy, 2016; 24:430–446. DOI:10.1038/mt.2016.10.
3.
LaoharaweeK, DeKelverRC, Podetz-PedersenKM, et al.Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol Ther, 2018; 26:1127–1136. DOI: 10.1016/j.ymthe.2018.03.002.
4.
NiuD, WeiH-J, LinL, et al.Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science, 2017; 357:1303–1307. DOI: 10.1126/science.aan4187.
5.
CanverMC, SmithEC, SherF, et al.BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 2015; 527:192–197. DOI: 10.1038/nature15521.
6.
WilsonJM. Interview with Jean Bennett, MD, PhD. Hum Gene Ther Clin Dev, 2018; 29:7–9. DOI:10.1089/humc.2018.29032.int.
7.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. New Engl J Med, 2017; 377:1713–1722. DOI: 10.1056/NEJMoa1706198.